Table 2. Expression of LAG-3 in post-NACT specimens and the association with clinicopathologic characteristics and other variables.
| Variable | Total (n=114) No. (%) | LAG-3 | p-value | |
|---|---|---|---|---|
| High (n=38) No. (%) | Low (n=76) No. (%) | |||
| Age (yr) | 0.140 | |||
| < 45 | 30 (26.3) | 10 (26.3) | 20 (26.3) | |
| ≥ 45, < 60 | 72 (63.2) | 21 (55.3) | 51 (67.1) | |
| ≥ 60 | 12 (10.5) | 7 (18.4) | 5 (6.6) | |
| Menstruation | 0.421 | |||
| Pre | 66 (57.9) | 24 (63.2) | 42 (55.3) | |
| Post | 48 (42.1) | 14 (36.8) | 34 (44.7) | |
| Tumor size (cm) | 0.959 | |||
| ≤2 | 46 (40.4) | 16 (42.1) | 30 (39.5) | |
| > 2, ≤ 5 | 50 (43.9) | 16 (42.1) | 34 (44.7) | |
| >5 | 18 (15.8) | 6 (15.8) | 12 (15.8) | |
| Histological grade | 0.227 | |||
| I, II | 48 (42.1) | 13 (34.2) | 35 (46.1) | |
| III | 66 (57.9) | 25 (65.8) | 41 (53.9) | |
| Nodal status | 0.023 | |||
| Positive | 64 (56.1) | 27 (71.1) | 37 (48.7) | |
| Negative | 50 (43.9) | 11 (28.9) | 39 (51.3) | |
| Ki-67 (%) | 0.330 | |||
| ≤ 14 | 24 (21.1) | 6 (15.8) | 18 (23.7) | |
| > 15 | 90 (78.9) | 32 (84.2) | 58 (76.3) | |
| PD-1 | < 0.001 | |||
| High | 33 (28.9) | 23 (60.5) | 10 (13.2) | |
| Low | 81 (71.1) | 15 (39.5) | 66 (86.8) | |
| CD8+TILs | 0.289 | |||
| High | 58 (50.9) | 22 (57.9) | 36 (47.4) | |
| Low | 56 (49.1) | 16 (42.1) | 40 (52.6) | |
| PD-L1 | 0.056 | |||
| High | 43 (37.7) | 19 (50.0) | 24 (31.6) | |
| Low | 71 (62.3) | 19 (50.0) | 52 (68.4) | |
LAG-3=lymphocyte-activation gene-3; NACT=neoadjuvant chemotherapy; PD-1=programmed death-1; TILs=tumor-infiltrating lymphocytes; PD-L1=programmed death ligand-1.